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LETTERS TO THE EDITOR
ERCC1 and Small Cell
Lung Cancer
To the Editor:
In the April issue of the Journal of
Thoracic Oncology, Skov et al.1 and
Chiappori et al.2 analyzed the role of
excision repair cross-complementing-1
(ERCC1) in small cell lung cancer
(SCLC), reporting immunohistochemical
expression in 17 of 186 (10%) patients
treated with platinum-based chemother-
apy (CT) and low level of expression by
immunofluorescence combined with auto-
mated quantitative analysis method, re-
spectively. Basically, these results seem to
witness a minor role of ERCC1 in SCLC,
as previously observed by Kim et al.,3
reporting ERCC1 immunostaining in 27%
of 130 patients with SCLC but no signif-
icant association with clinical response or
survival. By contrast, Lee at al.4 found
ERCC1 immunoreactivity in 17% of 77
patients with SCLC, but high ERCC1 ex-
pression was significantly related to poor
prognosis in limited disease (LD) (p 
0.026), while low ERCC1 expression
gave a significant benefit for patients
treated with platinum-based CT. Accord-
ing to Lee et al.,4 Ceppi et al.5 demon-
strated high gene ERCC1 levels in 43
(51%) of 85 patients with SCLC tested by
real-time PCR on paraffin-embedded sam-
ples. Despite no association being found
between ERCC1 and response to therapy,
patients with SCLC with LD and low
ERCC1 mRNA levels had a significant
longer survival than patients with LD-
SCLC and high ERCC1 levels (p 
0.012).5 This survival advantage in low
ERCC1/LD-SCLC was also maintained at
Cox’s multivariate analysis (p  0.014).5
All these previous experiences on
ERCC1 expression in SCLC are sum-
marized in Table 1.
Also, our multidisciplinary group
recently investigated the role of ERCC1
by immunohistochemistry (clone 8F1)
in a series of 105 patients with SCLC
(33 with LD and 72 with extensive
disease), all smokers (75 men and 30
women).
To have a better knowledge of the
correlation between ERCC1 expression
and response to platinum-based chemo-
therapy in SCLC patients, we arbitrarily
selected a population with a high rate of
nonresponder patients at first-line che-
motherapy (46 responders and 59 non-
responders). A cutoff of 10% of tumor
cells with at least a moderate staining
nuclear intensity (2) was recorded to
distinguish positive from negative cases.
All patients were treated with platinum-
based CT regimen plus etoposide.
Similar to the studies by Lee et
al.4 and Ceppi et al.,5 ERCC1 positivity
was found in 46 cases (43.8%), and its
expression significantly correlated with
tumor stage (negative staining in 70% of
LD and 50% of extensive disease; p 
0.046). Patients with LD with ERCC1
negative staining were significantly as-
sociated with better survival (p 
0.028). In addition, we did not observe a
significant correlation between ERCC1
expression and response to therapy nei-
ther in overall population nor in patients
subdivided by disease stage.
Of note, in three cases with double
biopsy before and after first-line CT,
ERCC1-negative tumor cells at diagno-
sis switched to positive in two cases,
while the remaining case maintained
ERCC1 expression.
In our hands, ERCC1 seems to be
a prognostic rather than a predictive
marker of response to platinum-based CT
also in SCLC, particularly in LD. How-
ever, there are at least two main critical
points limiting the use of ERCC1 as a
predictive factor in SCLC: (1) platinum-
based CT is the mainstay of first-line
treatment, and introduction of alterna-
tive therapies (i.e., targeted therapies or
platinum-free regimens) is promising
but far from the present; and (2) discrep-
ant results so far reported in studies on
ERCC1 expression as a predictive marker
in SCLC are mainly due to different
methodologies (i.e., various techniques
for expression detection and choice of a
reproducible cutoff in quoting positiv-
ity) adopted for ERCC1 evaluation in
limited series as found in non-SCLC. By
the way, because platinum-based CT
will remain the gold standard therapy in
future, retrospective and prospective
studies on large series of SCLC are
needed to determine validation of the
different methods testing ERCC1.
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ILD during Erlotinib
and Gefitinib
Treatment in Japanese
Patients with Non-
small Cell Lung Cancer
To the Editor:
Hotta et al. compared the inci-
dence and pattern of interstitial lung
disease (ILD) in Japanese patients with
non-small cell lung cancer receiving
treatment with epidermal growth factor
receptor (EGFR) tyrosine kinase inhibi-
tors (TKIs). Two different cohorts of
patients were compared: unselected pa-
tients treated with gefitinib between
2000 and 2003 and selected patients
with a lower proportion of known risk
factors for ILD treated with erlotinib in
2008.1 This article highlights the impor-
tance of appropriate patient selection to
minimize the risk of ILD with EGFR
TKIs: indeed, the authors concluded that
patient selection, because of recent
awareness of risk factors for ILD, may
explain their numerical difference in
ILD incidence between the two EGFR
TKIs in these different time frames. We
found the article interesting and were
encouraged to note that the authors ac-
knowledge numerous limitations in their
comparison. We would also like to point
out that Table 1 incorrectly stated that
8% of patients (rather than the correct
38% of patients) who were treated with
gefitinib had a poor performance status,
an independent risk factor for ILD, com-
pared with 20% of those who were
treated with erlotinib.
In 2002, AstraZeneca, the manu-
facturer of gefitinib, added ILD to the
list of known adverse reactions in the
prescribing information.2 Subsequently,
a large epidemiological study in Japa-
nese patients with non-small cell lung
cancer, designed and conducted by an
independent academic team together
with scientists from AstraZeneca, iden-
tified a number of risk factors for devel-
oping ILD (irrespective of whether the
patient received gefitinib or chemother-
apy).3 AstraZeneca added these risk fac-
tors to the prescribing information2 for
gefitinib in 2006 to provide this impor-
tant information to prescribers as a part
of proactive risk mitigation. The pre-
scribing information for gefitinib has
since been refined and updated several
times to enable clinicians and patients to
make informed prescribing choices: the
warning on this event expanded with
risk factors for mortality associated with
ILD, and frequency of ILD updated to
1.3% (based on the phase III clinical
program).2 This labeling has resulted in
increased awareness and appropriate pa-
tient selection, which is reflected by the
reduction in reporting rates of ILD with
EGFR TKIs. For gefitinib, the reported
incidence rate of ILD in Japan has re-
duced from 5.8% in 2003–20044 to the
current incidence rate of 1.28% (0.64%
in regions outside Japan) (AstraZeneca,
data on file).
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TABLE 1. Summary of the Studies Analyzing ERCC1 Expression in SCLC
Reference Cases Series Method Cutoff Results
Lee et al.4 77 (40 LD/37 ED) IHC (clone 8F1) 10% with 2 Overall, high ERCC1 expression in 17%. No association with
response to CT. High ERCC1 expression significantly
correlated with poor overall survival, particularly in LD.
Ceppi et al.5 85 (45 LD/40 ED) rt-PCR Median (5.3) High ERCC1 expression in 51%. Overall, no correlation with
survival and response to platinumVP16. Patients with LD
and low ERCC1 levels had significantly longer survival. In
LD, low ERCC1 expression is an independent prognostic
factor.
Kim et al.3 130 (18 LD/112 ED) IHC (clone 8F1) 10% ERCC1 expression in 27%. No correlation with survival and
response to platinum-based CT.
Skov et al.1 186 (63 LD/116 ED) IHC (clone 8F1) Positive/negative Positivity in 10% of SCLC. No significant association with
survival was observed. ERCC1 positive carcinoids had longer
survival that the negative ones.
Chiappori et al.2 100 (unknown stage) AQUA Not available Low expression levels when compared with RRM1 and
topoisomerase2alpha
This study 105 (33 LD/72 ED) IHC (clone 8F1) 10% with 2 Overall, ERCC1 expression in 46 cases (43.8%). ERCC1-
negative tumors had a significant correlation with LD and
better survival. ERCC1 expression did not significantly
correlated with response to first-line platinum-based CT.
ERCC1, excision repair cross complementing-1; SCLC, small cell lung cancer; LD, limited disease; ED, extensive disease; rt-PCR, real-time polymerase chain reaction; IHC,
immunohistochemistry; AQUA, immunofluorescence combined with automated quantitative analysis; CT, chemotherapy.
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